US.COR · Cencora

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.006324910225116,
        "turnoverUsdM": 372.79595366539,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.COR",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 308.0714,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4,
      "take_profit_price": 336.9975,
      "target_multiplier": 1.9,
      "technical_strength": 1.58,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2460593931017345,
    "stopLossPercent": 4.012649820450232,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 53.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 322.6625,
    "ma50": 314.4686,
    "close": 320.95,
    "prevClose": 323.32,
    "avgVolume20": 1188167,
    "volumeRatio": 0.98,
    "changePercent": -0.73
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.04581395070204386,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.9213883424292423,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.048931007748897,
      "volat_points": 0,
      "day_range_pct": 0.021779061480633626,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 53.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 72,
        "contribution": 3.6
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 16.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56,
        "contribution": 16.8
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 50.3,
    "details": [
      "基本面分析總分: 3.6/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 16.8/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.6,
      "資金流": 8.4,
      "市場環境": 6.2,
      "情緒分析": 6,
      "技術信號": 16.8,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 372.79595366539,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.COR",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.006324910225116,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141955203,
                "url": "https://finnhub.io/api/news?id=8eee7a83d373bc4efbfdc3a9256a021d3d5a7c3e26336b19d562516b608353a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.",
                "category": "company",
                "datetime": 1788898998,
                "headline": "Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks"
              },
              {
                "id": 141951994,
                "url": "https://finnhub.io/api/news?id=a375fbe02b4405ef0067332de8bf694ce053df54419ec167f9bdcd29649615cb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...",
                "category": "company",
                "datetime": 1788870332,
                "headline": "Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141437861,
                "url": "https://finnhub.io/api/news?id=619219ce6baf1e84960d05716fe0abf700065839d97653085b24f12474337225",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141425837,
                "url": "https://finnhub.io/api/news?id=04618d4900fe8b37179a5fec0859112f3acea6bc56cd79493d78642e495aae1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...",
                "category": "company",
                "datetime": 1788509254,
                "headline": "Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings?"
              },
              {
                "id": 141406371,
                "url": "https://finnhub.io/api/news?id=543a51cb36faa641af065609a5e92d9ec6ff38653264e75f2b2d0a30f222781c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings outlook following stronger-than-expected third-quarter results. The combination of expanded capabilities in cell and gene therapies and faster profit growth across its healthcare solutions segments highlights how Cencora is deepening its role in complex,...",
                "category": "company",
                "datetime": 1788475235,
                "headline": "What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders"
              },
              {
                "id": 141399268,
                "url": "https://finnhub.io/api/news?id=2ec6ee90c8383466911256286110d4360d06af68636e174e412366405b4fde12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]",
                "category": "company",
                "datetime": 1788441099,
                "headline": "Artisan Sold Cencora (COR) as Earnings Momentum Slowed"
              },
              {
                "id": 141260003,
                "url": "https://finnhub.io/api/news?id=4686df89d067221d433b4d9334e75d507527f5bcf24e4164cb3733c43ad98213",
                "image": "",
                "source": "Fintel",
                "related": "COR",
                "summary": "",
                "category": "company",
                "datetime": 1787208249,
                "headline": "RBC Capital Initiates Coverage of Cencora (COR) with Sector Perform Recommendation"
              },
              {
                "id": 141223240,
                "url": "https://finnhub.io/api/news?id=6527909585ff50c3ffd622f59d25a2a8135b62bc5d4161ef630603722acb0040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]",
                "category": "company",
                "datetime": 1786709161,
                "headline": "Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity"
              }
            ],
            "raw_source": [
              {
                "id": 142063302,
                "url": "https://finnhub.io/api/news?id=ad181144a7d06182ba609e0908d03dc6ded85f4ed97764dbd7f7ce1ac0017980",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.",
                "category": "company",
                "datetime": 1789062373,
                "headline": "AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142063433,
                "url": "https://finnhub.io/api/news?id=f57f6954e66790078ae5cddb82a24d663ad81113c4bbf68161a7e0e774309d17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
                "category": "company",
                "datetime": 1789062304,
                "headline": "2 S&P 500 Stocks with Exciting Potential and 1 We Question"
              },
              {
                "id": 142063354,
                "url": "https://finnhub.io/api/news?id=048a492322933b269d7e80caf13a16d0fcc27cc8948d27855f206759fbc84081",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.",
                "category": "company",
                "datetime": 1789057284,
                "headline": "Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142028746,
                "url": "https://finnhub.io/api/news?id=e63b6ec956820a26fe485ffe6e8aea85d06e12f3cc889695166a5af347783058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Despite lagging behind the Dow over the past 12 months, Cencora continues to receive a highly bullish outlook from Wall Street analysts.",
                "category": "company",
                "datetime": 1788956348,
                "headline": "Is Cencora Stock Underperforming the Dow?"
              },
              {
                "id": 141955203,
                "url": "https://finnhub.io/api/news?id=8eee7a83d373bc4efbfdc3a9256a021d3d5a7c3e26336b19d562516b608353a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.",
                "category": "company",
                "datetime": 1788898998,
                "headline": "Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks"
              },
              {
                "id": 141951994,
                "url": "https://finnhub.io/api/news?id=a375fbe02b4405ef0067332de8bf694ce053df54419ec167f9bdcd29649615cb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...",
                "category": "company",
                "datetime": 1788870332,
                "headline": "Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141951870,
                "url": "https://finnhub.io/api/news?id=4e7b1a2aeb0c009cfa4b796256f852bfd5d492e932be21782b3689b931c10da5",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "RBC Capital  analyst Ryan Halsted   reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.",
                "category": "company",
                "datetime": 1788863860,
                "headline": "RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target"
              },
              {
                "id": 141455383,
                "url": "https://finnhub.io/api/news?id=4521da65387b1edfe02b09e78249415553f3c231a03dbadecd6f07e26011f0f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.",
                "category": "company",
                "datetime": 1788550740,
                "headline": "Here's Why You Should Retain Cencora Stock in Your Portfolio for Now"
              },
              {
                "id": 141455037,
                "url": "https://finnhub.io/api/news?id=882e78db4092ee8e4a4f8c9153c570608198427b13f54f3413147816ac706bb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.",
                "category": "company",
                "datetime": 1788547801,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141437861,
                "url": "https://finnhub.io/api/news?id=619219ce6baf1e84960d05716fe0abf700065839d97653085b24f12474337225",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141430966,
                "url": "https://finnhub.io/api/news?id=082f1e05ae3af0a526e2c1843b2f6cab5ec7e14a8c1cb1c2413f010a199696d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.",
                "category": "company",
                "datetime": 1788532620,
                "headline": "Cencora Launches Cell and Gene Therapy Enablement for Health Systems"
              },
              {
                "id": 141425837,
                "url": "https://finnhub.io/api/news?id=04618d4900fe8b37179a5fec0859112f3acea6bc56cd79493d78642e495aae1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...",
                "category": "company",
                "datetime": 1788509254,
                "headline": "Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings?"
              },
              {
                "id": 141406371,
                "url": "https://finnhub.io/api/news?id=543a51cb36faa641af065609a5e92d9ec6ff38653264e75f2b2d0a30f222781c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings outlook following stronger-than-expected third-quarter results. The combination of expanded capabilities in cell and gene therapies and faster profit growth across its healthcare solutions segments highlights how Cencora is deepening its role in complex,...",
                "category": "company",
                "datetime": 1788475235,
                "headline": "What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders"
              },
              {
                "id": 141406350,
                "url": "https://finnhub.io/api/news?id=7f06d643160898f1cbdc391a8a9105109c98cd0a5edf1bf978d1a4c97a7e8a62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]",
                "category": "company",
                "datetime": 1788472375,
                "headline": "Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”"
              },
              {
                "id": 141403880,
                "url": "https://finnhub.io/api/news?id=2e84096df15ac30b56cad9794a7c930f96ca0a6d437a48ac470b179160eb83fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.",
                "category": "company",
                "datetime": 1788463320,
                "headline": "Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen"
              },
              {
                "id": 141398251,
                "url": "https://finnhub.io/api/news?id=328a82c3d457909e88b69b893d71448dd5d5c025b99eb4233343050a4eaa9df2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.",
                "category": "company",
                "datetime": 1788441720,
                "headline": "Is Generics Still a Quiet Profit Engine for Cardinal Health?"
              },
              {
                "id": 141399268,
                "url": "https://finnhub.io/api/news?id=2ec6ee90c8383466911256286110d4360d06af68636e174e412366405b4fde12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]",
                "category": "company",
                "datetime": 1788441099,
                "headline": "Artisan Sold Cencora (COR) as Earnings Momentum Slowed"
              },
              {
                "id": 141377069,
                "url": "https://finnhub.io/api/news?id=d2b0a78c5b2ec6bef921c8a712d6ecb1fbbbb7aa81af14819d5df457b1463590",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.",
                "category": "company",
                "datetime": 1788355800,
                "headline": "Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs"
              },
              {
                "id": 141362754,
                "url": "https://finnhub.io/api/news?id=2c3bd9c7fccc48120afd93d76c875e6f3df03acc9479b68de2005f1d9bbaca11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Accelerant, Shopify and Carpenter Technology delivered strong gains, while Zacks upgrades and model portfolios spotlight key performers.",
                "category": "company",
                "datetime": 1788182880,
                "headline": "Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus"
              },
              {
                "id": 141348564,
                "url": "https://finnhub.io/api/news?id=7009d4f82a8712cebfa86427db9a724d72e0b2b5febcd81764d5d26f56545d3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.",
                "category": "company",
                "datetime": 1788028861,
                "headline": "AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141361438,
                "url": "https://finnhub.io/api/news?id=940a43f5ddc818d2bd608a743ecdb586ed6fb5e91ade75734e7d1edb77b505aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.",
                "category": "company",
                "datetime": 1788023101,
                "headline": "Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141344500,
                "url": "https://finnhub.io/api/news?id=2727fe7b1d03d8cf5755c1adce1aae6e5a6d673d379ed9278ffd88c870e8566b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/29/Hallandale-Beach--Florida--Usa---Feb-12-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Walmart agreed to pay $50 million to settle a DOJ lawsuit alleging its pharmacies unlawfully filled opioid prescriptions.",
                "category": "company",
                "datetime": 1787961673,
                "headline": "Walmart Agrees to $50 Million Settlement With DOJ Over Alleged Opioid Prescription Violations, Calls Payout ‘Immaterial’"
              },
              {
                "id": 141363460,
                "url": "https://finnhub.io/api/news?id=c722c8496a561211d26704a9a80e75b0fd79a99d2432c59a004343711e4680c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "\"Not for distribution to United States news wire services or for dissemination in the United States.\"VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) (\"Camino\" or the \"Company\") is pleased to announce the closing of its previously announced private placements (together, the \"Offering\") for aggregate gross proceeds of C$15,223,109.",
                "category": "company",
                "datetime": 1787762400,
                "headline": "Camino Closes $5.8 Million Brokered Private Placement of Units and Concurrent $9.4 Million Non-Brokered Private Placement of Convertible Debentures"
              },
              {
                "id": 141323908,
                "url": "https://finnhub.io/api/news?id=661f453e83e60bc1b53b5d53f3b91a6df8a240d288f3f371da1af9f74141e344",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "It was reported on August 25, that Elizabeth S Campbell, Executive Vice President at Cencora (NYSE:COR) executed a significant insider sell, according to an SEC filing.\nWhat Happened: After conducting a thorough",
                "category": "company",
                "datetime": 1787742099,
                "headline": "Elizabeth S Campbell Takes Money Off The Table, Sells $3.66M In Cencora Stock"
              },
              {
                "id": 141362494,
                "url": "https://finnhub.io/api/news?id=813bbe30273839d5c9e39751e4840e5380adf79983ce68785f5bc9d92a450f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.",
                "category": "company",
                "datetime": 1787600940,
                "headline": "McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate"
              },
              {
                "id": 141362493,
                "url": "https://finnhub.io/api/news?id=a26caf7ebd42adc41c28417195d15ca548d9f7918e53a2033fe7bbaeb5ef1826",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1787600940,
                "headline": "Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?"
              },
              {
                "id": 141303070,
                "url": "https://finnhub.io/api/news?id=1bc7c8c3f2c66972d3399d77bb4313e98ddbdc8d97239280f5785bd552745225",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2281845986/image_2281845986.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. Read more here.",
                "category": "company",
                "datetime": 1787494920,
                "headline": "Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance"
              },
              {
                "id": 141273578,
                "url": "https://finnhub.io/api/news?id=39359255fee6dd1beadb269dd99f2e2f1d0813d68dd4371fa931522e517ddb8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "Get this week’s Dividend Champions, Contenders & Challengers update: dividend changes, upcoming ex-dividend dates, and pay dates. Read the full list here.",
                "category": "company",
                "datetime": 1787334897,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 23"
              },
              {
                "id": 141260003,
                "url": "https://finnhub.io/api/news?id=4686df89d067221d433b4d9334e75d507527f5bcf24e4164cb3733c43ad98213",
                "image": "",
                "source": "Fintel",
                "related": "COR",
                "summary": "",
                "category": "company",
                "datetime": 1787208249,
                "headline": "RBC Capital Initiates Coverage of Cencora (COR) with Sector Perform Recommendation"
              },
              {
                "id": 141263146,
                "url": "https://finnhub.io/api/news?id=6bebed1f2e3e68b35cbbd95600881bd12104e65e8e3c024f92136859172da6e4",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.",
                "category": "company",
                "datetime": 1787162437,
                "headline": "$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141255110,
                "url": "https://finnhub.io/api/news?id=150c2226d9f6e77977ee8c0027998f5892b00eec477ee0d98c77135b366d188f",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "RBC Capital  analyst Ryan Halsted   initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.",
                "category": "company",
                "datetime": 1787132773,
                "headline": "RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330"
              },
              {
                "id": 141251571,
                "url": "https://finnhub.io/api/news?id=dd9db39e8abddc3f2e8095ac1b6606266bc27875ea4002694cc82d39c229a18c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1083672712/image_1083672712.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "COR",
                "summary": "During the quarter, we initiated positions in GE Aerospace, Corning, STMicroelectronics and Robinhood.",
                "category": "company",
                "datetime": 1787101800,
                "headline": "Artisan Global Opportunities Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141223241,
                "url": "https://finnhub.io/api/news?id=33a2434b268e9c2c0fa89571638f2150a7ee2e9c0b89bccb945d9e3a0e34de88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.",
                "category": "company",
                "datetime": 1786736789,
                "headline": "AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141223240,
                "url": "https://finnhub.io/api/news?id=6527909585ff50c3ffd622f59d25a2a8135b62bc5d4161ef630603722acb0040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]",
                "category": "company",
                "datetime": 1786709161,
                "headline": "Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity"
              },
              {
                "id": 141215081,
                "url": "https://finnhub.io/api/news?id=46e1555335d1b3fb8660b90649ec0bdb67f2d339b6db31f86806d8269edc92c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in",
                "category": "company",
                "datetime": 1786690860,
                "headline": "5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call"
              },
              {
                "id": 141218551,
                "url": "https://finnhub.io/api/news?id=ae11daeda8d96877db82c0a10bfe918a675d25846e92a4e8064b2a6871c035f5",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.",
                "category": "company",
                "datetime": 1786639550,
                "headline": "If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141204220,
                "url": "https://finnhub.io/api/news?id=0d53e7cfc838cb3ace1409d01f73a7fdcde3e3ab900bbe384e3a289dc32023d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 futures ahead by roughly 0.6%, as investors focus on a key inflation update and what it could mean for interest rates. July CPI is expected at 3.4% year on year, with core inflation seen at 2.5%, which would suggest the cost of living is still rising but closer to the central bank’s comfort zone. At the same...",
                "category": "company",
                "datetime": 1786608546,
                "headline": "US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI"
              },
              {
                "id": 141201942,
                "url": "https://finnhub.io/api/news?id=87049698bf4459af6add0c1d50d42c36766ab980da8f92c3ffdc9fe68bb89f76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "US equity indexes ended mixed Wednesday amid stock gains by some major technology stocks and a four-",
                "category": "company",
                "datetime": 1786565681,
                "headline": "US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data"
              },
              {
                "id": 141200782,
                "url": "https://finnhub.io/api/news?id=3b5f954cd1b2c6018690020dd2e9080b368c3c279b3aaf21fa9af59eb700c847",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t",
                "category": "company",
                "datetime": 1786564721,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 141195030,
                "url": "https://finnhub.io/api/news?id=3a160a35b8171cc0055d79c795a9f5b630ffb9514f619fcf427e897552198643",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1786561501,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 141201944,
                "url": "https://finnhub.io/api/news?id=46f47e185eacdbfa38541a9505f664b5ebb5e17edeb61ab5dae921c3947a001d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Revenue hit $84.8 billion as GLP-1 sales surged 25% despite manufacturer price headwinds.",
                "category": "company",
                "datetime": 1786547685,
                "headline": "Cencora (COR) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 141193106,
                "url": "https://finnhub.io/api/news?id=108b6eb45cf4cc80a945dccddcb20e9433d76a346102b3bac10208632e8679ac",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "Wondering which stocks are making significant price gaps? Explore the S&P500 index on Wednesday to find the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1786545301,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 141201945,
                "url": "https://finnhub.io/api/news?id=ff3b8e2fb99bc3cd66641392a6de719daceaefd5c4237f3b9f962600c6592bc1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.",
                "category": "company",
                "datetime": 1786544156,
                "headline": "Is Wall Street Bullish or Bearish on Cencora Stock?"
              },
              {
                "id": 141209844,
                "url": "https://finnhub.io/api/news?id=c25c7297158d160b395d0f672295014e5ac82e93cf063299e0ef2e825ea0f54b",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the "Company" or "Cencora") separate from the prime vendor agreement began moving outside the Company. The prime",
                "category": "company",
                "datetime": 1786538766,
                "headline": "Cencora Says Certain Walgreens Volume Moves Outside Cencora From July 1, 2026; Reaffirms FY26 Adj Diluted EPS Guidance Range Of $17.75-$17.95; Says Prime Vendor Agreement With Walgreens Remains Unchanged"
              },
              {
                "id": 141192693,
                "url": "https://finnhub.io/api/news?id=1a51c3fda625137f05bd7a8622dd3db9cd4f97aa3ff563d6f1aa5511d9562da4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "COR",
                "summary": "As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786538101,
                "headline": "Which S&P500 stocks are moving before the opening bell on Wednesday?"
              },
              {
                "id": 141200621,
                "url": "https://finnhub.io/api/news?id=a08e7c7fa18be82606ea2feeb7ddeeada1626fe5e95e301c926252196ccedab8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.",
                "category": "company",
                "datetime": 1786481221,
                "headline": "AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141201490,
                "url": "https://finnhub.io/api/news?id=b27d87e3c8947f158bf4d832fe91f3e13a1b1c088d17bd7f1566ddeb622996ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "COR",
                "summary": "S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall.  Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point.  Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.",
                "category": "company",
                "datetime": 1786454176,
                "headline": "S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results"
              },
              {
                "id": 141185958,
                "url": "https://finnhub.io/api/news?id=9dceabb509c6b4c2d44e38caac1aaa73c920b39d9457c65637e7ce654aa6d157",
                "image": "",
                "source": "Benzinga",
                "related": "COR",
                "summary": "Wells Fargo  analyst Stephen Baxter   maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $331 to $395.",
                "category": "company",
                "datetime": 1786438738,
                "headline": "Wells Fargo Maintains Overweight on Cencora, Raises Price Target to $395"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 48,
            "discarded_article_count": 39
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1397983.3333333333,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1237850,
              "avg_vol_20": 1260640,
              "avg_vol_30": 1397983.3333333333,
              "range_pct_10": 0.06128674368946119,
              "range_pct_20": 0.1143479634102519,
              "range_pct_30": 0.11677824842566607,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.885454046900893,
              "dist_to_20d_high": 0.05243417827741067,
              "down_shrink_days": 3,
              "breakout_level_20d": 338.70999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5248130068372502
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.006324910225116,
              "turnoverUsdM": 372.79595366539,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.COR",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 308.0714,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4,
            "take_profit_price": 336.9975,
            "target_multiplier": 1.9,
            "technical_strength": 1.58,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2460593931017345,
          "stopLossPercent": 4.012649820450232,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.COR",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 6.4393,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.01
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 7.13
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0628
    },
    "kdj": {
      "d": 53.95,
      "j": -2.75,
      "k": 35.05,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 55.42
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 1491061,
      "recentSlope": 41366.1,
      "previousSlope": 242880
    },
    "rsi": 55.97,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 338.71,
      "position": "SAR喺價上",
      "distancePct": 5.53,
      "previousTrend": "上升"
    },
    "ma50": 314.4686,
    "macd": {
      "macd": 3.8730370282692093,
      "trend": "中性偏多",
      "signal": 4.864543577863374,
      "histogram": -0.9915065495941651
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 322.6266,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.98,
      "score": 4,
      "avgVolume": 1188167,
      "currentVolume": 1161539
    },
    "derived": {
      "ma20": 322.6625,
      "ma50": 314.4686,
      "prevClose": 323.32,
      "avgVolume10": 1269844,
      "avgVolume20": 1188167,
      "changePercent": -0.73,
      "avgVolumeForScore": 1188167
    },
    "ma_cross": {
      "ma20": 322.6625,
      "ma50": 314.4686,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 322.3235,
      "prevMa50": 313.7092,
      "spreadPct": 2.61,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 307.8006,
      "upper": 337.5244,
      "position": "中間"
    },
    "rsi_short": 27.75,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.98
    }
  }
}

{
  "close": 320.95,
  "volume": 1161539,
  "changePercent": -0.73
}